FDA approves Boehringer's lung disease drug

The U.S. Food and Drug Administration on Friday approved German drugmaker Boehringer Ingelheim's Ofev capsules for a rare lung disorder. The drug is first FDA-approved treatment for this condition, the FDA said in a statement. The drug is aimed at slowing the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis, an autoimmune condition. Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis, which is another interstitial lung condition.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001051 seconds